U.S. markets closed
  • S&P 500

    3,298.46
    +51.87 (+1.60%)
     
  • Dow 30

    27,173.96
    +358.56 (+1.34%)
     
  • Nasdaq

    10,913.56
    +241.26 (+2.26%)
     
  • Russell 2000

    1,474.91
    +23.09 (+1.59%)
     
  • Crude Oil

    40.04
    -0.27 (-0.67%)
     
  • Gold

    1,864.30
    -12.60 (-0.67%)
     
  • Silver

    22.99
    -0.21 (-0.91%)
     
  • EUR/USD

    1.1637
    -0.0038 (-0.33%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • GBP/USD

    1.2744
    -0.0007 (-0.06%)
     
  • USD/JPY

    105.5000
    +0.0980 (+0.09%)
     
  • BTC-USD

    10,744.73
    +9.38 (+0.09%)
     
  • CMC Crypto 200

    230.19
    +12.36 (+5.67%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.82 (+0.51%)
     

Regeneron Says Its Coronavirus Antibody Cocktail Shows Promise For Both Prevention, Treatment In Animal Testing

Shivdeep Dhaliwal

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Monday that a non-peer-reviewed study indicated its antibody drug combination both prevented and treated COVID-19 in animals, as earlier reported by Reuters.

What Happened

The drugmaker noted a cocktail of two monoclonal antibodies adminstered to rhesus macaques and hamsters was able to “almost completely block establishment of virus infection.”

In a second study, the animals were administered a much higher level of the virus, where the antibodies still managed to minimize the infection, Regeneron said, according to Reuters. The prophylactic effect was greatly diminished with a lower dose of the drug combination, it added.

Animals infected with the antibodies were reportedly able to clear the virus faster than those administered a placebo.

Researchers involved in the study said, citing data, that the therapy may offer clinical benefits for both treatment and prevention of COVID-19.

The New York-based drugmaker is conducting late-stage clinical trials in humans to assess the antibody’s efficacy in treating and preventing COVID-19, Reuters reported.

Why It Matters

The firm has signed a contract worth $450 million with the government to supply the treatment, should it clear the trials. Eli Lilly and Co (NYSE: LLY) is also said to be testing a similar treatment. 

Multiple vaccine candidates from Johnson & Johnson (NYSE: JNJ), Moderna Inc (NASDAQ: MRNA), Pfizer Inc (NYSE: PFE) are either in late-stage human trials or about to undergo such trials. 

President Donald Trump on Monday said a coronavirus vaccine could be available far ahead of the administration's original target of the end of the year, CNBC reported. The president added leading vaccine candidates are being mass-produced in advance, so that they're ready for distribution as, and if, they get regulatory approval. 

Price Action 

Regeneron shares closed nearly 2.1% higher at $645.18 on Monday and added another 0.67% in the after-hours.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.